Advaxis receives USPTO patent for Listeria vaccine The U Click to read more .S. Trademark and Patent Workplace has approved Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy company, intellectual property security to patent program 11/223,945 – a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu , with all the company’s proprietary listeriolysin O fusion platform technology. The patent also extends protection to LLO-HER2/neu proteins independent of live Listeria which can be used as proteins vaccines. This patent will be Advaxis’ 29th in its growing intellectual property portfolio, stated Advaxis EVP of Science and Operations Dr.
Advisen’s webinar to discuss the current state of MMSEA regulations and enforcement Allied World Assurance Company Holdings, Ltd announced today that Allied World’s Sam Carucci, U.S. Casualty Claims Supervisor, will end up being speaking on a panel for Advisen’s webinar at 11am on Mon, November 23, 2009, discussing Medicare, Medicaid and SCHIP Extension Work of 2007 and Professional Liability’s Hidden Burdens. With the passing of the MMSEA, Congress offers sought to safeguard the Medicare program from paying expenses regarded as the obligation of an insurance provider, self-insured organization or various other entity.